

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 January 2023 (12.01.2023)



(10) International Publication Number
WO 2023/283620 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) *A61P 21/00* (2006.01)
A61K 39/395 (2006.01) *C07K 14/79* (2006.01)
A61K 48/00 (2006.01) *C12N 15/113* (2010.01)

(21) International Application Number:

PCT/US2022/073536

(22) International Filing Date:

08 July 2022 (08.07.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/220,000 09 July 2021 (09.07.2021) US
63/316,905 04 March 2022 (04.03.2022) US

(71) Applicant: **DYNE THERAPEUTICS, INC.** [US/US];
1560 Trapelo Road, Waltham, MA 02451 (US).

(72) Inventors: **ZANOTTI, Stefano**; 1560 Trapelo Road,
Waltham, MA 02451 (US). **PICARIELLO, Tyler**; 1560
Trapelo Road, Waltham, MA 02451 (US). **WEEDEN,**
Timothy; 1560 Trapelo Road, Waltham, MA 02451 (US).
DESJARDINS, Cody, A.; 1560 Trapelo Road, Waltham,
MA 02451 (US). **SUBRAMANIAN, Romesh, R.**; 9 Alan
Street, Framingham, MA 01701 (US). **QATANANI, Mo-**
hammed, T.; 1560 Trapelo Road, Waltham, MA 02451
(US). **QUINN, Brendan**; 45 East Newton Street #320,
Boston, MA 02118 (US). **NAJIM, John**; 1560 Trapelo
Road, Waltham, MA 02451 (US).

(74) Agent: **BALICH, Jason, W.** et al.; Wolf, Greenfield &
Sacks, P.c., 600 Atlantic Avenue, Boston, MA 02210-2206
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY




FIG. 1A

(57) Abstract: The present application relates to oligonucleotides (e.g., antisense oligonucleotides such as gapmers) designed to target DMPK RNAs and targeting complexes for delivering the oligonucleotides to cells (e.g., muscle cells) and uses thereof, particularly uses relating to treatment of disease. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DMPK.

WO 2023/283620 A1